Strategic Screening for Infectious Diseases (Tuberculosis, HIV, HBV, HCV) Amongst Migrants in France
NCT ID: NCT02959684
Last Updated: 2018-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
70000 participants
OBSERVATIONAL
2017-04-14
2019-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Cohort of People Starting Treatment for Tuberculosis Disease in France (FrenchTB)
NCT06893757
Screening for Tuberculosis in Pregnancy
NCT04098341
Serological Test for the Diagnosis of TB
NCT02898623
Testing for Tuberculosis in the United Kingdom HIV Infected Population
NCT02712671
Improving the Diagnostic of Tuberculosis
NCT02861768
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It is a prospective multi-centric observational study validating screening tests for HIV/HBV/HCV in two phases:
* Phase 1: a risk score will be validated, including a qualitative study analyzing its acceptability
* Phase 2: its performance will be compared with that of a screening targeted based on the country of origin The phase 1 and phase 2 will include respectively 10.000 and 5000 participants.
For tuberculosis, the efficacy of the improved version of TB screen will be compared with a systematic radiography.
Participation to this study will be voluntary and independent from the delivery of a residence permit. Participants will be informed of it and will systematically receive information about prevention of those infectious diseases.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Giving informed consent (oral consent)
Exclusion Criteria
* Persons not understanding the questionnaire
* Persons aware of their HIV, HBV or HCV positive status
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Paris 7 - Denis Diderot
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Martin Duracinsky
Dr
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
OFII Bordeaux
Bordeaux, , France
OFII Cergy
Cergy, , France
OFII Clermont-Ferrand
Clermont-Ferrand, , France
OFII Grenoble
Grenoble, , France
OFII Lille
Lille, , France
OFII Lyon
Lyon, , France
OFII Marseille
Marseille, , France
OFII Melun
Melun, , France
OFII Metz
Metz, , France
OFII Montpellier
Montpellier, , France
OFII Montrouge
Montrouge, , France
OFII Nantes
Nantes, , France
OFII Nice
Nice, , France
OFII Orléans
Orléans, , France
OFII Reims
Reims, , France
OFII Rennes
Rennes, , France
OFII Rouen
Rouen, , France
OFII Toulouse
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Frédérique Thonon
Role: primary
Sabrina Lakhdari
Role: primary
Frédérique Thonon
Role: primary
Sabrina Lakhdari
Role: primary
Frédérique Thonon
Role: primary
Frédérique Thonon
Role: primary
Frédérique Thonon
Role: primary
Sabrina Lakhdari
Role: primary
Frédérique Thonon
Role: primary
Frédérique Thonon
Role: primary
Frédérique Thonon
Role: primary
Frédérique Thonon
Role: primary
Frédérique Thonon
Role: primary
Frédérique Thonon
Role: primary
Frédérique Thonon
Role: primary
Sabrina Lakhdari
Role: primary
Frédérique Thonon
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Duracinsky M, Yaya I, Yombo-Kokule L, Bessonneau P, Thonon F, Rousset-Torrente O, Roudot-Thoraval F, Lert F, Zucman D, Chassany O. Development of a risk prediction score for screening for HBV, HCV and HIV among migrants in France: results from a multicentre observational study (STRADA study). BMJ Open. 2024 Jun 5;14(6):e075315. doi: 10.1136/bmjopen-2023-075315.
Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, Warszawski J, Steinmetz J, Coste D, Meyer JF, Leiser S, Giordanella JP, Gueguen R, Desenclos JC. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol. 2010 Apr;82(4):546-55. doi: 10.1002/jmv.21734.
Schneeberger Geisler S, Helbling P, Zellweger JP, Altpeter ES. Screening for tuberculosis in asylum seekers: comparison of chest radiography with an interview-based system. Int J Tuberc Lung Dis. 2010 Nov;14(11):1388-94.
d'Almeida KW, Kierzek G, de Truchis P, Le Vu S, Pateron D, Renaud B, Semaille C, Bousquet V, Simon F, Guillemot D, Lert F, Cremieux AC; Emergency Department HIV-Screening Group. Modest public health impact of nontargeted human immunodeficiency virus screening in 29 emergency departments. Arch Intern Med. 2012 Jan 9;172(1):12-20. doi: 10.1001/archinternmed.2011.535. Epub 2011 Oct 24.
d'Almeida KW, Pateron D, Kierzek G, Renaud B, Semaille C, de Truchis P, Simon F, Leblanc J, Lert F, Le Vu S, Cremieux AC. Understanding providers' offering and patients' acceptance of HIV screening in emergency departments: a multilevel analysis. ANRS 95008, Paris, France. PLoS One. 2013 Apr 29;8(4):e62686. doi: 10.1371/journal.pone.0062686. Print 2013.
Bottero J, Boyd A, Gozlan J, Carrat F, Nau J, Pauti MD, Rougier H, Girard PM, Lacombe K. Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage. Open Forum Infect Dis. 2015 Oct 26;2(4):ofv162. doi: 10.1093/ofid/ofv162. eCollection 2015 Dec.
Haukoos JS, Lyons MS, Lindsell CJ, Hopkins E, Bender B, Rothman RE, Hsieh YH, Maclaren LA, Thrun MW, Sasson C, Byyny RL. Derivation and validation of the Denver Human Immunodeficiency Virus (HIV) risk score for targeted HIV screening. Am J Epidemiol. 2012 Apr 15;175(8):838-46. doi: 10.1093/aje/kwr389. Epub 2012 Mar 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PROunit-STRADA2016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.